| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1016616914 |
| P356 | DOI | 10.1007/S11060-008-9685-3 |
| P932 | PMC publication ID | 3022437 |
| P698 | PubMed publication ID | 18810326 |
| P5875 | ResearchGate publication ID | 23273129 |
| P2093 | author name string | Sarah J Nelson | |
| Susan Chang | |||
| Andrea Pirzkall | |||
| Kathleen R Lamborn | |||
| Soonmee Cha | |||
| Forrest W Crawford | |||
| Suja Saraswathy | |||
| P2860 | cites work | The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. | Q55476501 |
| Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. | Q55477357 | ||
| Microvessel density is a prognostic indicator for patients with astroglial brain tumors. | Q55479921 | ||
| Analysis of brain tumors using 1H magnetic resonance spectroscopy. | Q55480606 | ||
| Univariate and multivariate statistical analysis of high-grade gliomas: the relationship of radiation dose and other prognostic factors. | Q55484473 | ||
| Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. | Q55487073 | ||
| Measuring blood volume and vascular transfer constant from dynamic,T2*-weighted contrast-enhanced MRI | Q57530352 | ||
| Evaluation of four postprocessing methods for determination of cerebral blood volume and mean transit time by dynamic susceptibility contrast imaging | Q60483542 | ||
| Choline-containing compounds in human astrocytomas studied by 1H NMR spectroscopy in vivo and in vitro | Q72729047 | ||
| Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI | Q28281455 | ||
| Serial evaluation of patients with brain tumors using volume MRI and 3D 1H MRSI. | Q30579563 | ||
| Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors | Q30620964 | ||
| An automated technique for the quantitative assessment of 3D-MRSI data from patients with glioma | Q30627262 | ||
| Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors | Q30657481 | ||
| Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics | Q30700912 | ||
| Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma | Q31015437 | ||
| What the clinician can learn from MRS lactate measurements | Q31161282 | ||
| Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hy | Q32012802 | ||
| In vivo lactate editing with simultaneous detection of choline, creatine, NAA, and lipid singlets at 1.5 T using PRESS excitation with applications to the study of brain and head and neck tumors | Q32034068 | ||
| A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival | Q34108339 | ||
| Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM. | Q34498073 | ||
| Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis | Q35800783 | ||
| Localized in vivo 1H magnetic resonance spectroscopy and in vitro analyses of heterogeneous brain tumors | Q36688896 | ||
| MR imaging of high-grade cerebral gliomas: value of diffusion-weighted echoplanar pulse sequences | Q36742386 | ||
| Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications | Q39495167 | ||
| Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas | Q40525983 | ||
| Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland. | Q40799629 | ||
| Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer | Q41715418 | ||
| Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas | Q41722307 | ||
| Factors determining survival of patients with malignant gliomas diagnosed by stereotactic biopsy | Q41771524 | ||
| Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma | Q42063495 | ||
| Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence | Q42686851 | ||
| Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors | Q43570065 | ||
| Glucocorticoid dependency as a prognostic factor in radiotherapy for cerebral gliomas | Q43583383 | ||
| MR-spectroscopy guided target delineation for high-grade gliomas | Q43655485 | ||
| Registration of images from sequential MR studies of the brain | Q44634964 | ||
| Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy | Q44742482 | ||
| 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI. | Q44849163 | ||
| Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume | Q44866834 | ||
| Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach | Q45015296 | ||
| Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. | Q45997469 | ||
| Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury. | Q46007003 | ||
| Dynamic susceptibility contrast perfusion imaging of radiation effects in normal-appearing brain tissue: changes in the first-pass and recirculation phases. | Q46024068 | ||
| Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging | Q46463935 | ||
| Volume MRI and MRSI techniques for the quantitation of treatment response in brain tumors: presentation of a detailed case study | Q46662511 | ||
| Feasibility of dynamic susceptibility contrast perfusion MR imaging at 3T using a standard quadrature head coil and eight-channel phased-array coil with and without SENSE reconstruction | Q46990726 | ||
| Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas | Q48276582 | ||
| Considerations in applying 3D PRESS H-1 brain MRSI with an eight-channel phased-array coil at 3 T. | Q48348165 | ||
| Perfusion, diffusion and spectroscopy values in newly diagnosed cerebral gliomas. | Q48503860 | ||
| High-resolution 1H NMR spectroscopy studies of extracts of human cerebral neoplasms | Q48516914 | ||
| Corpus callosum involvement as a prognostic factor for patients with high-grade astrocytoma. | Q48734363 | ||
| The role of diffusion-weighted imaging in patients with brain tumors. | Q48836254 | ||
| Metabolism of human gliomas: assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET. | Q48846610 | ||
| Radiation-induced regional cerebral blood volume (rCBV) changes in normal brain and low-grade astrocytomas: quantification and time and dose-dependent occurrence. | Q55475357 | ||
| P433 | issue | 1 | |
| P921 | main subject | patient | Q181600 |
| P304 | page(s) | 69-81 | |
| P577 | publication date | 2008-09-23 | |
| P1433 | published in | Journal of Neuro-Oncology | Q15752119 |
| P1476 | title | Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy | |
| P478 | volume | 91 |
| Q27334114 | 7.0-T magnetic resonance imaging characterization of acute blood-brain-barrier disruption achieved with intracranial irreversible electroporation |
| Q55461252 | A prognostic model based on preoperative MRI predicts overall survival in patients with diffuse gliomas. |
| Q26826862 | Advanced magnetic resonance imaging methods for planning and monitoring radiation therapy in patients with high-grade glioma |
| Q36339461 | Advances in neuro-oncology imaging. |
| Q30910766 | Anatomical, functional and molecular biomarker applications of magnetic resonance neuroimaging |
| Q39852579 | Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience. |
| Q34480495 | Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma |
| Q33888366 | Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI. |
| Q41438064 | Association of dynamic susceptibility contrast enhanced MR Perfusion parameters with prognosis in elderly patients with glioblastomas |
| Q39439133 | Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen |
| Q37697784 | Characterization of metabolites in infiltrating gliomas using ex vivo ¹H high-resolution magic angle spinning spectroscopy |
| Q39817583 | Characterization of the serum metabolome following radiation treatment in patients with high-grade gliomas |
| Q34935862 | Chemoirradiation for glioblastoma multiforme: the national cancer institute experience |
| Q39685607 | Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma |
| Q35028897 | Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab |
| Q37014722 | Comparison of DSC-MRI post-processing techniques in predicting microvascular histopathology in patients newly diagnosed with GBM |
| Q49274965 | Diffusion Weighted/Tensor Imaging, Functional MRI and Perfusion Weighted Imaging in Glioblastoma-Foundations and Future. |
| Q64117470 | Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging |
| Q35815291 | Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial |
| Q36641544 | Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation |
| Q48182133 | Elderly patients with newly diagnosed glioblastoma: can preoperative imaging descriptors improve the predictive power of a survival model? |
| Q48318624 | Evaluation of absolute and normalized apparent diffusion coefficient (ADC) values within the post-operative T2/FLAIR volume as adverse prognostic indicators in glioblastoma |
| Q48788960 | Gross total resection plays a leading role in survival of patients with glioblastoma multiforme. |
| Q48787869 | Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab. |
| Q34132735 | Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors |
| Q28081811 | Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H(+) symporters |
| Q90650277 | Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy |
| Q48930260 | Identification of a candidate biomarker from perfusion MRI to anticipate glioblastoma progression after chemoradiation. |
| Q33657683 | Imaging of brain tumors: MR spectroscopy and metabolic imaging |
| Q41810793 | Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer |
| Q34440284 | Implementation of 3 T lactate-edited 3D 1H MR spectroscopic imaging with flyback echo-planar readout for gliomas patients |
| Q36555913 | Integration method of 3D MR spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boost |
| Q39476804 | Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma |
| Q31113520 | Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma |
| Q45892703 | Intraoperative visualization of residual tumor: the role of perfusion-weighted imaging in a high-field intraoperative magnetic resonance scanner |
| Q40629371 | Lactate levels with glioblastoma multiforme |
| Q64076906 | Low perfusion compartments in glioblastoma quantified by advanced magnetic resonance imaging and correlated with patient survival |
| Q39312420 | MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives. |
| Q31015256 | Magnetic Resonance (MR) Metabolic Imaging in Glioma. |
| Q26751140 | Magnetic resonance spectroscopy - Revisiting the biochemical and molecular milieu of brain tumors |
| Q38961858 | Metabolomic Screening of Tumor Tissue and Serum in Glioma Patients Reveals Diagnostic and Prognostic Information |
| Q53262770 | Morphological and flow cytometric analysis of cell infiltration in glioblastoma: a comparison of autopsy brain and neuroimaging. |
| Q39647863 | Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas |
| Q55456990 | Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project. |
| Q31115540 | Non-invasive metabolic imaging of brain tumours in the era of precision medicine |
| Q49566176 | Normalization of ADC does not improve correlation with overall survival in patients with high-grade glioma (HGG). |
| Q28544667 | Nuclear Overhauser Enhancement imaging of glioblastoma at 7 Tesla: region specific correlation with apparent diffusion coefficient and histology |
| Q35771783 | Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma |
| Q50092029 | Predicting complexity of tumor removal and postoperative outcome in patients with high-grade gliomas. |
| Q42115077 | Pretreatment serum lactate level as a prognostic biomarker in patients undergoing supratentorial primary brain tumor resection |
| Q37496863 | Prognostic value of preoperative dynamic contrast-enhanced MRI perfusion parameters for high-grade glioma patients. |
| Q36392140 | Quantifying the CDK inhibitor VMY-1-103's activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI. |
| Q38998271 | Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma |
| Q44362904 | Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival |
| Q36048224 | Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging |
| Q34246635 | Repeatability of edited lactate and other metabolites in astrocytoma at 3T. |
| Q38747896 | Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma. |
| Q36889298 | Semi-Automated Volumetric and Morphological Assessment of Glioblastoma Resection with Fluorescence-Guided Surgery |
| Q48874095 | Separation and quantification of lactate and lipid at 1.3 ppm by diffusion-weighted magnetic resonance spectroscopy. |
| Q37348479 | Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab |
| Q34977347 | Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme. |
| Q36792743 | Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging |
| Q26778444 | The use of dynamic nuclear polarization (13)C-pyruvate MRS in cancer |
| Q38947519 | The use of hyperpolarized carbon-13 magnetic resonance for molecular imaging |
| Q47615969 | Therapeutic Targeting of the Pyruvate Dehydrogenase Complex/Pyruvate Dehydrogenase Kinase (PDC/PDK) Axis in Cancer |
| Q33574572 | Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma |
| Q48614301 | Unmet needs in the treatment of glioblastoma. |
| Q35914541 | Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma |
| Q35689991 | Volumetric and MGMT parameters in glioblastoma patients: survival analysis |
| Q52151865 | Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination. |
Search more.